异种I型胶原蛋白注射治疗萎缩性痤疮疤痕的前瞻性研究。

IF 1.3 Q3 DERMATOLOGY
Skin Appendage Disorders Pub Date : 2025-08-01 Epub Date: 2025-02-14 DOI:10.1159/000544166
Aikaterini Gkouvi, Aikaterini Tsiogka, Andrea Corbo, Antonios Tsimpidakis, Stamatios Gregoriou
{"title":"异种I型胶原蛋白注射治疗萎缩性痤疮疤痕的前瞻性研究。","authors":"Aikaterini Gkouvi, Aikaterini Tsiogka, Andrea Corbo, Antonios Tsimpidakis, Stamatios Gregoriou","doi":"10.1159/000544166","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of acne scars includes laser therapies, microneedling, chemical peels, and dermal fillers. Herein, we sought to assess the efficacy and safety of heterologous type I collagen injections (HT1Cs) on atrophic acne scars.</p><p><strong>Methods: </strong>One hundred milligrams of HT1C were injected beneath each atrophic acne scar on patients with atrophic acne scars graded as 2, 3, or 4 according to the Goodman and Baron's acne scar grading system. Patients underwent four treatment sessions at 2-week intervals, and they were evaluated for up to week 52, using the above-mentioned grading system and a 0-10 visual analogue scale (VAS).</p><p><strong>Results: </strong>30 patients (9 males: 21 females; median [range] age 32 [18-50] years) were enrolled in the study. At baseline, 10 (33%), 17 (57%), and 3 (10%) patients presented with grade 2, 3, and 4 scaring. At 3-month follow-up, 7 (23%), 16 (53%), 4 (13%), and 3 (10%) of patients presented with grade 1, 2, 3, and 4 scaring, respectively. At the same visit, physicians rated the mean improvement as 6.8, while patients rated it slightly higher at 7.2. The observed improvements were sustained up to 12 months. The mean patients' satisfaction rate at 3 months was 7.4. No major adverse events were reported throughout the entire duration of the follow-up period.</p><p><strong>Conclusion: </strong>The results of the present study highlight the efficacy, sustainability, and safety of HT1C injections in treating atrophic acne scars.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 4","pages":"316-319"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324723/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Heterologous Type I Collagen Injections in Treating Atrophic Acne Scars: A Prospective Study.\",\"authors\":\"Aikaterini Gkouvi, Aikaterini Tsiogka, Andrea Corbo, Antonios Tsimpidakis, Stamatios Gregoriou\",\"doi\":\"10.1159/000544166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Treatment of acne scars includes laser therapies, microneedling, chemical peels, and dermal fillers. Herein, we sought to assess the efficacy and safety of heterologous type I collagen injections (HT1Cs) on atrophic acne scars.</p><p><strong>Methods: </strong>One hundred milligrams of HT1C were injected beneath each atrophic acne scar on patients with atrophic acne scars graded as 2, 3, or 4 according to the Goodman and Baron's acne scar grading system. Patients underwent four treatment sessions at 2-week intervals, and they were evaluated for up to week 52, using the above-mentioned grading system and a 0-10 visual analogue scale (VAS).</p><p><strong>Results: </strong>30 patients (9 males: 21 females; median [range] age 32 [18-50] years) were enrolled in the study. At baseline, 10 (33%), 17 (57%), and 3 (10%) patients presented with grade 2, 3, and 4 scaring. At 3-month follow-up, 7 (23%), 16 (53%), 4 (13%), and 3 (10%) of patients presented with grade 1, 2, 3, and 4 scaring, respectively. At the same visit, physicians rated the mean improvement as 6.8, while patients rated it slightly higher at 7.2. The observed improvements were sustained up to 12 months. The mean patients' satisfaction rate at 3 months was 7.4. No major adverse events were reported throughout the entire duration of the follow-up period.</p><p><strong>Conclusion: </strong>The results of the present study highlight the efficacy, sustainability, and safety of HT1C injections in treating atrophic acne scars.</p>\",\"PeriodicalId\":21844,\"journal\":{\"name\":\"Skin Appendage Disorders\",\"volume\":\"11 4\",\"pages\":\"316-319\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324723/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin Appendage Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000544166\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin Appendage Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000544166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

治疗痤疮疤痕包括激光疗法,微针,化学脱皮,和真皮填充物。在此,我们试图评估异种I型胶原注射(ht1c)治疗萎缩性痤疮疤痕的疗效和安全性。方法:根据Goodman和Baron的痤疮疤痕分级系统,对2、3、4级的萎缩性痤疮疤痕患者,在每条萎缩性痤疮疤痕下注射100毫克HT1C。患者以2周为间隔进行4次治疗,并使用上述分级系统和0-10视觉模拟量表(VAS)对患者进行评估,直至第52周。结果:30例患者(男9例,女21例;中位[范围]年龄为32岁[18-50]岁)。基线时,10名(33%)、17名(57%)和3名(10%)患者表现为2级、3级和4级惊吓。在3个月的随访中,分别有7名(23%)、16名(53%)、4名(13%)和3名(10%)患者表现为1级、2级、3级和4级惊吓。在同一次访问中,医生给平均改善评分为6.8分,而患者给的评分略高,为7.2分。观察到的改善持续了12个月。患者3个月平均满意度为7.4。在整个随访期间未报告重大不良事件。结论:本研究结果突出了HT1C注射治疗萎缩性痤疮疤痕的有效性、可持续性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of Heterologous Type I Collagen Injections in Treating Atrophic Acne Scars: A Prospective Study.

Introduction: Treatment of acne scars includes laser therapies, microneedling, chemical peels, and dermal fillers. Herein, we sought to assess the efficacy and safety of heterologous type I collagen injections (HT1Cs) on atrophic acne scars.

Methods: One hundred milligrams of HT1C were injected beneath each atrophic acne scar on patients with atrophic acne scars graded as 2, 3, or 4 according to the Goodman and Baron's acne scar grading system. Patients underwent four treatment sessions at 2-week intervals, and they were evaluated for up to week 52, using the above-mentioned grading system and a 0-10 visual analogue scale (VAS).

Results: 30 patients (9 males: 21 females; median [range] age 32 [18-50] years) were enrolled in the study. At baseline, 10 (33%), 17 (57%), and 3 (10%) patients presented with grade 2, 3, and 4 scaring. At 3-month follow-up, 7 (23%), 16 (53%), 4 (13%), and 3 (10%) of patients presented with grade 1, 2, 3, and 4 scaring, respectively. At the same visit, physicians rated the mean improvement as 6.8, while patients rated it slightly higher at 7.2. The observed improvements were sustained up to 12 months. The mean patients' satisfaction rate at 3 months was 7.4. No major adverse events were reported throughout the entire duration of the follow-up period.

Conclusion: The results of the present study highlight the efficacy, sustainability, and safety of HT1C injections in treating atrophic acne scars.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.00
自引率
10.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信